JP2010064961A - Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same - Google Patents
Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same Download PDFInfo
- Publication number
- JP2010064961A JP2010064961A JP2008230499A JP2008230499A JP2010064961A JP 2010064961 A JP2010064961 A JP 2010064961A JP 2008230499 A JP2008230499 A JP 2008230499A JP 2008230499 A JP2008230499 A JP 2008230499A JP 2010064961 A JP2010064961 A JP 2010064961A
- Authority
- JP
- Japan
- Prior art keywords
- oral
- flora
- bacteria
- antibacterial activity
- catechin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000001580 bacterial effect Effects 0.000 title claims description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 89
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 59
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 235000005487 catechin Nutrition 0.000 claims abstract description 55
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 54
- 229950001002 cianidanol Drugs 0.000 claims abstract description 54
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 41
- 210000000214 mouth Anatomy 0.000 claims abstract description 39
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 24
- 230000000813 microbial effect Effects 0.000 claims abstract description 23
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 23
- 208000002925 dental caries Diseases 0.000 claims abstract description 21
- 239000000230 xanthan gum Substances 0.000 claims abstract description 17
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 17
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 17
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 17
- 208000001388 Opportunistic Infections Diseases 0.000 claims abstract description 13
- 230000001680 brushing effect Effects 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000194019 Streptococcus mutans Species 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229960003085 meticillin Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 241000186045 Actinomyces naeslundii Species 0.000 claims description 2
- 241001135221 Prevotella intermedia Species 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 16
- 239000000499 gel Substances 0.000 description 64
- 238000012360 testing method Methods 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 15
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 10
- 239000008272 agar Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- 239000013065 commercial product Substances 0.000 description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 3
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 3
- 239000000120 Artificial Saliva Substances 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- WMBWREPUVVBILR-NQIIRXRSSA-N (-)-gallocatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-NQIIRXRSSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 230000007406 plaque accumulation Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【課題】 歯周病菌、う蝕原因菌、日和見感染症原因菌に対する高い抗菌活性を示し、口腔内常在菌叢に対しては抗菌活性を示さず、よって菌叢バランスを崩すことが無い、優れた高い口腔常在菌叢調整能を有する組成物を提供する。また、簡便かつ有効な方法で口腔ケアを行うことができる方法を提供する。
【解決手段】 所定の粘性を有する口腔常在菌叢調整剤で、歯周病菌、う蝕原因菌、日和見感染症原因菌の少なくとも一種に対しては抗菌活性を示すが、口腔内常在菌には抗菌活性を示さず、かつ保湿作用を有する口腔常在菌叢調整剤である。有効量のカテキンとキサンタンガムを含有していることが好ましい。特にジェル剤であることが好ましい。また、上記口腔常在菌叢調整剤を口腔内に、塗布、歯磨き、経口摂取、喫食の少なくとも一つの手法にて適用することを特徴とする口腔常在菌叢調整方法である。
【選択図】 図1PROBLEM TO BE SOLVED: To show a high antibacterial activity against periodontal disease bacteria, caries-causing bacteria, and opportunistic infection-causing bacteria, and does not show antibacterial activity against oral resident flora, and thus does not disrupt the flora balance. Disclosed is a composition having an excellent ability to adjust the normal oral flora. Moreover, the method which can perform oral care by a simple and effective method is provided.
SOLUTION: An oral resident flora adjusting agent having a predetermined viscosity, which exhibits antibacterial activity against at least one of periodontal disease bacteria, caries-causing bacteria, and opportunistic infection-causing bacteria. Is an oral resident flora regulator that does not exhibit antibacterial activity and has a moisturizing action. It preferably contains an effective amount of catechin and xanthan gum. A gel agent is particularly preferable. Further, the present invention is a method for adjusting the normal microbial flora characterized by applying the oral microbial flora adjusting agent to the oral cavity by at least one of application, brushing, oral intake, and eating.
[Selection] Figure 1
Description
本発明は、口腔常在菌叢調整剤に関し、特に、保湿効果を有する口腔ケア用のジェル化剤としてキサンタンガムを用いることで、抗菌作用を有するカテキンを口腔常在菌叢の状態を良好に保つように調整することを可能とした口腔常在菌叢調整剤に関する。また、本発明は、これを用いた口腔常在菌叢調整方法に関する。 The present invention relates to an oral microbial flora adjusting agent, and in particular, by using xanthan gum as a gelling agent for oral care having a moisturizing effect, catechin having an antibacterial action is kept in a good state of the oral resident flora. It is related with the oral cavity normal flora regulator which made it possible to adjust. The present invention also relates to a method for adjusting the normal oral flora using the same.
ヒトの口腔内では700種を超える極めて多種類の細菌が見出されており、また、その数も多く、粘膜面に恒常的に集合体、すなわち菌叢を形成している。この口腔内菌叢は、複雑な相互作用により、そのバランスが保たれており、外来性細菌に拮抗することで、その侵入感染を防止し、すなわち抵抗性を付与する機能なども担っている。しかし、この菌叢中には日和見菌と呼ばれる細菌も少なくない。この細菌は健康体に対しては通常病原性を発揮しないが、宿主の免疫低下などにより感染症の原因となってしまう。特に、口腔内における常在細菌の増加と遷移は、う蝕や歯周病などの口腔内感染症の原因となるばかりではなく、感染性心内膜炎、心筋梗塞、肺炎、早産や低体重児出産などの全身性疾患を起こす可能性についても報告されている。 In the human oral cavity, extremely many types of bacteria exceeding 700 species have been found, and the number of the bacteria is large, and an aggregate, that is, a flora is constantly formed on the mucosal surface. This intraoral flora is maintained in a balanced state by complex interactions, and has a function of preventing invasion, that is, imparting resistance by antagonizing foreign bacteria. However, there are many bacteria called opportunistic bacteria in this flora. Although this bacterium usually does not exert pathogenicity on healthy bodies, it may cause infections due to decreased immunity of the host. In particular, the increase and transition of resident bacteria in the oral cavity not only cause oral infections such as caries and periodontal disease, but also infective endocarditis, myocardial infarction, pneumonia, premature birth and low weight The possibility of causing systemic diseases such as childbirth has also been reported.
さらに、近年の高齢者の増加と共に、高齢者の口腔感染症の予防及び口腔衛生の向上は、極めて重要な課題となっている。特に要介護高齢者等では、自立高齢者に比べ口腔内にCandida albicansなどの日和見菌が検出される割合が増えてくることが知られている(非特許文献1)。その様な高齢者において嚥下障害が起こると、日和見菌を含む口腔内細菌が呼吸器系に侵入する機会が増え、肺炎を発症する可能性が危惧されている。従って、口腔内を日和見菌の少ない健康的な口腔細菌叢にすることが重要である。 Furthermore, with the recent increase in the number of elderly people, prevention of oral infections and improvement of oral hygiene among the elderly people are extremely important issues. In particular, it is known that elderly people requiring nursing care and the like are more likely to detect opportunistic bacteria such as Candida albicans in the oral cavity than independent elderly people (Non-patent Document 1). When dysphagia occurs in such elderly people, there is a concern that oral bacteria including opportunistic bacteria may increase the respiratory system and develop pneumonia. Therefore, it is important to make the oral cavity a healthy oral bacterial flora with less opportunistic bacteria.
口腔内の状態で、特に、う蝕や歯周病の予防については、これまで多数の研究が行われている。また、個別の細菌や口腔細菌叢全体に対する対策としても、これまで様々な研究が行われている。 Numerous studies have been conducted so far on the prevention of dental caries and periodontal disease in the oral cavity. In addition, various studies have been conducted so far as countermeasures against individual bacteria and the entire oral bacterial flora.
例えば特許文献1には、歯周病の原因菌となるポリフィロモナス・ジンジバリスの頬粘膜上皮細胞表層への付着を阻害することを目的として(−)−エピガロカテキンガレート、(−)−エピカテキンガレート、(−)−ガロカテキンガレートの少なくとも一つを含む歯周病原因菌付着阻害用組成物が開示されている。特許文献1に開示の組成物は、特定の細菌を付着させないことで感染を防止しており、所謂抗菌作用とは若干異なるアプローチを取っている。
For example,
特許文献2には、う蝕及び歯周病の予防に有効な組成物としてカテキン類緑体化合物を含有することが開示されており、特に口腔内細菌であるストレプトコッカス・ミュータンスに対する抗菌性試験において優れた結果を示している。この特許文献2においては、一般論として抗生物質や殺菌剤が口腔内細菌を非選択的に死滅させて常在菌叢の均衡を崩し、菌交代症を引き起こすことを従来の問題として記載しているが、実際の技術としては特定の細菌に対する抗菌性を示す組成物を提案しているため、口腔細菌叢に対する影響やこの調整能については検討も示唆もしていない。
一方、非病原性の口腔内常在菌の生育に影響を与えることなく、う蝕や歯周病原因菌に対して有効な組成物も多々研究されている。例えば、特許文献3に開示の漢方薬抽出エキスを含有する口腔用組成物、特許文献4に開示のココア分を有効成分とする抗歯周病菌組成物、特許文献5に開示のガングリオシドを有効成分とする口腔内細菌叢改善剤などが提案されている。これらでは、有用菌である非病原性口腔内常在菌に対する影響試験が、ある程度で示され検討されているが、実際に口腔内でも同様の効果を得られるか否かについては不明である。
On the other hand, many compositions that are effective against caries and periodontal disease-causing bacteria have been studied without affecting the growth of non-pathogenic oral resident bacteria. For example, the composition for oral cavity containing the extract of the Chinese medicine disclosed in
さらに、特許文献6には、口腔衛生に有用な物質、例えば植物ポリフェノールやバクテリオシンといった抗菌作用を有する物質と、粘性を発現する物質、例えばキサンタンガムなどを含有し、その粘性を加水量により調節できる口腔ケア組成物に関する発明が開示されている。そして、抗菌作用を有する物質として緑茶カテキンを開示している。この発明では、口腔衛生に有用な物質を口腔内にいかにして所定の時間で滞留させ、成分を徐放させることを目的としている。従って、その評価も溶出性、すなわち滞留性を評価するにとどまり、有効成分や組成物についての実際の抗菌活性や口腔内常在菌叢についての影響、すなわち調整能については検討されていない。 Furthermore, Patent Document 6 contains substances useful for oral hygiene, such as substances having antibacterial action such as plant polyphenols and bacteriocin, and substances that develop viscosity, such as xanthan gum, and the viscosity can be adjusted by the amount of water added. An invention relating to an oral care composition is disclosed. And the green tea catechin is disclosed as a substance which has an antibacterial action. The object of the present invention is to allow a substance useful for oral hygiene to stay in the oral cavity for a predetermined time and to release components gradually. Therefore, the evaluation is limited only to the dissolution property, that is, the retention property, and the actual antibacterial activity and the effect on the oral resident flora of the active ingredient and the composition, that is, the adjusting ability has not been studied.
上記のように、非病原性の口腔内常在菌叢に影響を与えることなく、う蝕原因菌や歯周病原因菌に対して有効な組成物の開発が求められていた。また、高齢者においては、唾液分泌量が少なくなる場合が多く、これは口腔衛生上、重大な問題となっていた。また一般的に、口腔の清掃は歯ブラシを使用するが、介護士の助けが必要な要介護高齢者等の場合、完全な口腔の清掃は非常に困難であり、口腔清掃が不十分になることが多くなる。そのため、一般的な歯ブラシによる口腔清浄を補助するための短時間で効率のよい口腔ケア法の開発が求められていた。 As described above, there has been a demand for the development of a composition effective against caries-causing bacteria and periodontal disease-causing bacteria without affecting the non-pathogenic oral resident flora. Moreover, in elderly people, the amount of saliva secretion often decreases, which has been a serious problem in oral hygiene. Generally, a toothbrush is used to clean the oral cavity. However, in the case of elderly people requiring care who need help from a caregiver, complete oral cleaning is very difficult and oral cleaning is insufficient. Will increase. Therefore, there has been a demand for the development of an effective oral care method in a short time to assist oral cleaning with a general toothbrush.
そこで、本発明の目的は、う蝕原因菌、歯周病原因菌や日和見感染症原因菌に対して高い抗菌活性を示す一方、口腔内常在菌叢に対して、特に有用菌に対して抗菌活性を示さず、よって大きな影響を与えないことで菌叢バランスを崩すこと無く、すなわち、極めて優れた口腔常在菌叢調整能を有し、簡便かつ有効な方法で用いることができ、さらに、保湿効果をも付与することができる組成物を提供する点にある。 Therefore, the object of the present invention is to provide high antibacterial activity against caries-causing bacteria, periodontal disease-causing bacteria and opportunistic infection-causing bacteria, while against oral resident flora, especially against useful bacteria. Does not show antibacterial activity, and therefore does not significantly affect the flora balance, that is, has an extremely excellent ability to adjust the normal oral flora, and can be used in a simple and effective manner. It is in providing a composition capable of imparting a moisturizing effect.
上記の従来の問題点に鑑み、本発明者らは鋭意研究を進めたところ、抗菌作用を有するカテキンを保湿作用物質であるキサンタンガムによってジェル化することにより、う蝕原因菌、歯周病原因菌や日和見感染症原因菌には高い抗菌活性を示すが、口腔内の正常常在菌叢には影響を与えず、菌叢バランスを崩すことがないこと、かつ、これが高い保湿作用を示すことを見出し、本発明を完成するに至った。 In view of the above-mentioned conventional problems, the present inventors have conducted extensive research, and by gelling catechin having antibacterial action with xanthan gum which is a moisturizing agent, caries-causing bacteria, periodontal disease-causing bacteria. It exhibits high antibacterial activity against bacteria that cause opportunistic infections, but does not affect the normal resident flora in the oral cavity, does not disrupt the flora balance, and exhibits high moisturizing action. The headline and the present invention were completed.
すなわち、本発明の一態様は、う蝕原因菌、歯周病原因菌や日和見感染症原因菌に対しては抗菌活性を示すが、口腔内常在菌には抗菌活性を示さず、所定の粘性及び保湿作用を有する口腔常在菌叢調整剤である。 That is, one embodiment of the present invention shows antibacterial activity against caries-causing bacteria, periodontal disease-causing bacteria and opportunistic infection-causing bacteria, but does not exhibit antibacterial activity in oral resident bacteria, Oral resident flora regulator with viscosity and moisturizing action.
本発明による口腔常在菌叢調整剤には、有効量のカテキンを含有していることが好ましく、その含有量としては好ましくは0.05重量%〜0.5重量%である。 The oral resident flora regulator according to the present invention preferably contains an effective amount of catechin, and the content thereof is preferably 0.05% by weight to 0.5% by weight.
そして、本発明による口腔常在菌叢調整剤には、有効量の保湿作用物質を含有していることが好ましい。この時、前記保湿作用物質としては、キサンタンガム、カラギーナン及びヒアルロン酸からなる群から選ばれる少なくとも一つの物質であることが好ましく、キサンタンガムが最も好ましい。この場合に、キサンタンガムの含有量としては、好ましくは1.0重量%〜5.0重量%である。 And it is preferable that the oral cavity normal flora regulator by this invention contains the effective amount of a moisturizing substance. At this time, the moisturizing substance is preferably at least one substance selected from the group consisting of xanthan gum, carrageenan and hyaluronic acid, and most preferably xanthan gum. In this case, the content of xanthan gum is preferably 1.0% by weight to 5.0% by weight.
一方、本発明による口腔常在菌叢調整剤は、20〜25℃におけるB型粘度計による粘度が2300〜8000mPa・sであることを特徴とする。そして、その剤型としては、ジェル剤であることが好ましい。 On the other hand, the oral cavity normal flora adjusting agent according to the present invention is characterized in that the viscosity by a B-type viscometer at 20 to 25 ° C. is 2300 to 8000 mPa · s. And as the dosage form, it is preferable that it is a gel agent.
本発明による口腔常在菌叢調整剤では、特に、歯周病菌である、Porphyromonas gingivalis、Aggregatibacter actinomycetemcomitans、Prevotella intermedia、及びFusobacterium nucleatumの少なくとも一種、う蝕原因菌であるActinomyces naeslundii及びStreptococcus mutansの少なくとも一種及び/又は日和見感染症原因菌であるCandida albicans、メチシリン耐性黄色ブドウ球菌(MRSA)の少なくとも一種に抗菌活性を示す。 The oral resident flora regulator according to the present invention is, in particular, at least one species of Porphyromonas gingivalis, Aggregaactacteractinutiumcedicomitans, Prevotella intermedium, and Fusobacterium nucleatum, which are at least one kind of bacteria that are periodontal disease bacteria. And / or at least one of Candida albicans and methicillin-resistant Staphylococcus aureus (MRSA) that are opportunistic infection-causing bacteria.
また、本発明の他の一態様は、前記いずれかに記載の口腔常在菌叢調整剤を口腔内に、塗布、歯磨き、経口摂取、喫食の少なくとも一つの手法にて適用することを特徴とする口腔常在菌叢調整方法である。 In addition, another aspect of the present invention is characterized in that the oral resident flora adjusting agent according to any one of the above is applied to the oral cavity by at least one method of application, brushing, oral intake, and eating. This is a method for adjusting the oral resident flora.
本発明による口腔常在菌叢調整方法においては、前記口腔常在菌叢調整剤にカテキンが含有され、当該口腔常在菌叢調整剤の1回の適用において含まれるカテキン量が10〜100mgの範囲であることが好ましい。 In the method for adjusting the oral resident flora according to the present invention, the catechin is contained in the oral microbial flora adjusting agent, and the amount of catechin contained in one application of the oral resident flora adjusting agent is 10 to 100 mg. A range is preferable.
本発明による口腔常在菌叢調整剤は、歯周病菌、う蝕原因菌や日和見感染症原因菌に対しては抗菌活性を示すが、口腔内常在菌には抗菌活性を示さず、所定の粘性を有し、かつ、高い保湿作用を有する。従って、所定の粘性を有するジェルとすることで、有効成分の口腔内での滞留時間が延長され、溶液の場合に比較して顕著に高い抗菌活性を提供できる。さらに、好ましいカテキンとキサンタンガムとの組合せにおいては、有用菌などを含む口腔内常在菌に対して抗菌性を示さず、すなわち、口腔常在菌叢に対する影響がなく、菌叢バランスを崩すことがない。従って、う蝕原因菌、歯周病原因菌や日和見感染症原因菌に対する抗菌活性と相まって、極めて優れた口腔常在菌叢調整能を示すことになる。その上、保湿作用物質、例えばキサンタンガムを適用することで、非常に高い保湿効果を提供することができる。
また、本発明の口腔常在菌叢調整方法では、塗布、歯磨き、経口摂取、喫食などの簡便な手法により、本発明の口腔常在菌叢調整剤を適用するのみである。従って、非常に簡便な方法により、本発明の優れた口腔常在菌叢調整能を利用することができる。
Oral resident flora regulator according to the present invention exhibits antibacterial activity against periodontal disease bacteria, caries-causing bacteria and opportunistic infection-causing bacteria, but does not exhibit antibacterial activity against oral resident bacteria, And has a high moisturizing action. Therefore, by using a gel having a predetermined viscosity, the residence time of the active ingredient in the oral cavity is extended, and it is possible to provide a significantly higher antibacterial activity than in the case of a solution. Furthermore, the preferred combination of catechin and xanthan gum does not exhibit antibacterial activity against oral resident bacteria including useful bacteria and the like, that is, has no effect on oral resident bacterial flora and may disrupt the bacterial flora balance. Absent. Therefore, in combination with antibacterial activity against caries-causing bacteria, periodontal disease-causing bacteria, and opportunistic infection-causing bacteria, it exhibits extremely excellent ability to adjust the normal oral flora. In addition, applying a moisturizing agent such as xanthan gum can provide a very high moisturizing effect.
Moreover, in the method for adjusting the normal microbial flora of the present invention, the oral microbial flora adjusting agent of the present invention is only applied by a simple method such as application, brushing, oral intake, and eating. Therefore, it is possible to use the excellent ability of adjusting the normal microbial flora of the present invention by a very simple method.
以下、本発明を詳細に説明するが、本発明は以下に述べる個々の形態には限定されない。 Hereinafter, the present invention will be described in detail, but the present invention is not limited to the individual forms described below.
本発明は、歯周病菌、う蝕原因菌や日和見感染症原因菌に対しては抗菌活性を示すが、口腔内常在菌には抗菌活性を示さず、所定の粘性及び保湿作用を有する口腔常在菌叢調整剤であり、好ましくは、有効量のカテキンを含有し、また有効量のキサンタンガムを含有する。 The present invention shows antibacterial activity against periodontal disease bacteria, caries-causing bacteria and opportunistic infection-causing bacteria, but does not show antibacterial activity against oral resident bacteria, and has a predetermined viscosity and moisturizing action. It is a resident flora adjusting agent, and preferably contains an effective amount of catechin and also contains an effective amount of xanthan gum.
本発明による口腔常在菌叢調整剤においては、抗菌作用を有するカテキンを含有することが好ましい。本発明に用いられるカテキンはエピ体、ヒドロキシ体、没食子酸エステル体等を含むものであり、単独または混合物で用いることが出来る。なお本発明においては、入手が簡便であること、風味が好ましいこと等から、混合物としてのカテキンを用いることが好ましい。また、合成品、天然物からの抽出物等はこれを問わず用いることができる。 In the oral cavity normal flora adjusting agent by this invention, it is preferable to contain the catechin which has an antimicrobial effect. The catechins used in the present invention include epi-forms, hydroxy-forms, gallate esters and the like, and can be used alone or in a mixture. In the present invention, it is preferable to use catechin as a mixture because it is easily available and has a preferable flavor. In addition, synthetic products, extracts from natural products, and the like can be used regardless of this.
本発明の口腔常在菌叢調整剤に含まれるカテキンの含有量は、0.05重量%〜0.5重量%が好ましく、0.1重量%〜0.3重量%がさらに好ましい。カテキン含量が0.5重量%を超えると、カテキン由来の苦味が発生し、風味の点で適さない。また、カテキン含量が0.05重量%未満だと、本発明で要求する口腔常在菌叢調整作用が発揮されない。 The content of catechin contained in the oral resident flora regulator of the present invention is preferably 0.05% by weight to 0.5% by weight, and more preferably 0.1% by weight to 0.3% by weight. If the catechin content exceeds 0.5% by weight, catechin-derived bitterness is generated, which is not suitable in terms of flavor. If the catechin content is less than 0.05% by weight, the oral resident flora adjusting action required in the present invention is not exhibited.
本発明の口腔常在菌叢調整剤には、保湿作用物質を含有することが好ましい。保湿作用物質としてはキサンタンガム、カラギーナン、ヒアルロン酸などが例示され、単独または組み合わせて用いることができる。また、特にキサンタンガムが好ましい。これら保湿作用物質は、通常の食品添加用のものをそのまま用いることができる。 It is preferable that the oral resident flora regulator of the present invention contains a moisturizing agent. Examples of moisturizing agents include xanthan gum, carrageenan, hyaluronic acid and the like, which can be used alone or in combination. Moreover, xanthan gum is particularly preferable. These moisturizing substances can be used as they are for normal food addition.
本発明の口腔常在菌叢調整剤中に含まれる保湿作用物質、例えばキサンタンガムの含有量としては、1.0重量%〜5.0重量%が好ましく、2.0重量%〜4.0重量%がさらに好ましい。保湿作用を有する物質の含有量が5.0重量%を超えたり、1.0重量%未満だと、口腔内での滞留性や徐放性、保湿効果の観点から十分な効果を得られない。 The content of a moisturizing agent, for example, xanthan gum, contained in the oral resident flora regulator of the present invention is preferably 1.0% by weight to 5.0% by weight, and 2.0% by weight to 4.0% by weight. % Is more preferable. If the content of the substance having a moisturizing action exceeds 5.0% by weight or less than 1.0% by weight, sufficient effects cannot be obtained from the viewpoint of retention in the oral cavity, sustained release, and moisturizing effect. .
本発明の口腔常在菌叢調整剤には、上記の化合物以外にも、本発明の口腔常在菌叢調整剤の効果やその粘性の状態を阻害しない範囲で、一般的な口腔ケア用組成物に用いられている添加物や食品に添加される一般的な食品添加物を用いることができる。 In addition to the above-mentioned compounds, the oral resident flora adjusting agent of the present invention is a general composition for oral care within a range that does not inhibit the effect of the oral resident flora adjusting agent of the present invention and the viscosity state thereof. Additives used in foods and general food additives added to foods can be used.
本発明の口腔常在菌叢調整剤は、一般的な口腔ケア用組成物を製造する工程にて適宜製造することができる。
本発明の口腔常在菌叢調整剤では、所定の粘性を有していることが必須であり、有効物質の滞留性や徐放性の観点から、B型粘度計(温度:20〜25℃)により測定した場合、好ましくは2300〜8000mPa・s、より好ましくは2400〜7000mPa・s、さらに好ましくは、2500〜6000mPa・sの粘度を有する。
The oral resident flora adjusting agent of the present invention can be appropriately produced in the process of producing a general oral care composition.
In the oral resident flora adjusting agent of the present invention, it is essential to have a predetermined viscosity. From the viewpoint of retention of active substances and sustained release, a B-type viscometer (temperature: 20 to 25 ° C. ) Is preferably 2300 to 8000 mPa · s, more preferably 2400 to 7000 mPa · s, and still more preferably 2500 to 6000 mPa · s.
本発明の口腔常在菌叢調整剤では、上記の好ましい所定の粘性を有する必要があり、この粘性を有するものであれば、その剤型としては液剤、ジェル剤、クリーム剤、軟膏剤などの形態を取ることができる。ジェル剤は、投与、摂取、塗布などの取り扱い性や、口腔内での滞留性、徐放性の点からも最も好ましい。また、ジェル剤の場合、上記の好ましい範囲を満たすことからも好ましい剤型といえる。 In the oral cavity normal flora adjusting agent of the present invention, it is necessary to have the above-mentioned preferable predetermined viscosity, and as long as it has this viscosity, its dosage form includes liquids, gels, creams, ointments, etc. Can take form. Gels are most preferable from the viewpoints of handling properties such as administration, ingestion, and application, retention in the oral cavity, and sustained release. Moreover, in the case of a gel agent, it can be said that it is a preferable dosage form from satisfy | filling said preferable range.
本発明の口腔常在菌叢調整剤の特徴として、う蝕原因菌、歯周病原因菌や日和見感染症原因菌には高い抗菌活性を示すが、口腔内正常常在菌叢には影響を与えず、よって菌叢バランスを崩すことがないことから口腔衛生状態を常に良い状態に調整しうることである。特に、本発明の口腔常在菌叢調整剤は、歯周病菌としてPorphyromonas gingivalis、Aggregatibacter actinomycetemcomitans、Prevotella intermedia、及びFusobacterium nucleatumの内の少なくとも一種に対して抗菌活性を示す。またう蝕原因菌としてActinomyces naeslundii及びStreptococcus mutansの少なくとも一種に対して抗菌活性を示す。またさらに日和見感染症原因菌として、Candida albicans、メチシリン耐性黄色ブドウ球菌(MRSA)の少なくとも一種に対して抗菌活性を示す。 The oral resident flora regulator of the present invention is characterized by high antibacterial activity against caries-causing bacteria, periodontal disease-causing bacteria, and opportunistic infection-causing bacteria. Therefore, the oral hygiene condition can be always adjusted to a good condition since the bacterial flora balance is not lost. In particular, the oral flora regulator of the present invention has antibacterial activity against at least one of the activity of Porphyromonas gingivalis, Aggrebacteractinactinometicites, Prevotella intermedia, and Fusobacterium nucleatum as periodontal disease bacteria. Further, it exhibits antibacterial activity against at least one of Actinomyces naeslundii and Streptococcus mutans as caries-causing bacteria. Furthermore, it exhibits antibacterial activity against at least one of Candida albicans and methicillin-resistant Staphylococcus aureus (MRSA) as opportunistic infection-causing bacteria.
本発明の口腔常在菌叢調整剤は、口腔内への塗布、歯磨き、飲用(経口摂取)、喫食等の幅広い使用状態や使用場面に応じて適用することができる。例えば本発明の口腔常在菌叢調整剤を経口摂取する場合、この時の投与量としては、カテキンを基準にして10〜100mgが好ましい。本発明の調整剤中の成分濃度について、カテキンでは上記の濃度範囲となるものが好ましく、また、キサンタンガムでは所定の粘性の状態を維持することができる上記の濃度範囲のものが好ましい。
適用時期については、通常の食事後、あるいは就寝前が好ましい。特に好ましくは、夕食後就寝前に適用し、何も摂取せずに就寝することである。
The oral microbial flora adjusting agent of the present invention can be applied according to a wide range of usage states and usage scenes such as application to the oral cavity, tooth brushing, drinking (oral intake), and eating. For example, when the oral resident flora regulator of the present invention is orally ingested, the dose at this time is preferably 10 to 100 mg based on catechin. With regard to the component concentration in the regulator of the present invention, catechin preferably has the above-mentioned concentration range, and xanthan gum preferably has the above-mentioned concentration range capable of maintaining a predetermined viscosity state.
The application time is preferably after a normal meal or before going to bed. Particularly preferably, it is applied after dinner and before going to bed, and goes to bed without taking anything.
以下、本発明を実施例を挙げて説明するが、本発明はこれにより限定されるものではない。なお、本明細書において、%の表示は特に明示しない限り、重量%を示す。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated, this invention is not limited by this. In the present specification, unless otherwise indicated,% indicates weight%.
尚、実施例中、菌株名にATCCと記載された菌株は、American Type Culture Collectionから入手した基準株、菌株名にJCMと記載された菌株は、独立行政法人理化学研究所バイオリソースセンターの微生物材料開発室から入手した基準株、FDCは、Forsyth Dental Centernoの保有菌株、IFOは、The institute for Fermentation, Osakaの保有菌株、MTは、Osaka University Dental School Hospitalの保有菌株、NIDRは、The National Institute of Dental Researchの保有菌株、NUDは、Nihon University School of Dentistryの保有菌株、TIは、Tokai Universityの保有菌株、WVUは、West Virginia Universityの保有菌株である。また、Escherichia coliは、すべてNihon University School of Dentistryの保有菌株である。 In the examples, the strain described as ATCC in the strain name is a reference strain obtained from the American Type Culture Collection, and the strain described as JCM in the strain name is a microbial material development of RIKEN BioResource Center. Reference strain obtained from the laboratory, FDC is the possession strain of Forsyth Dental Centerno, IFO is the strain of The Institute for Fermentation, Osaka possession strain, MT is the strain of Osaka University Dental School Research possessed strain, NUD is Nihon University School School Held strains of Dentistry, TI is holding strains of Tokai University, WVU is held strains of West Virginia University. In addition, Escherichia coli is a strain possessed by Nihon University School of Dentry.
[実施例1]口腔微生物に対するカテキンジェルの抗菌活性
本発明による口腔常在菌叢調整剤として口腔ケア用ジェル(以下、他の実施例を含めて口腔常在菌叢調整ジェルと称する場合がある)の抗菌活性について試験を行った。対照にはカテキンを含まないジェルを用いた。
[Example 1] Antibacterial activity of catechin gel against oral microorganisms Oral care gel according to the present invention (hereinafter sometimes referred to as oral normal flora adjusting gel including other examples) ) Was tested for antibacterial activity. A gel containing no catechin was used as a control.
具体的には、ジェル(商品名:トロメイク、明治乳業株式会社製)に対して抽出カテキン及び精製カテキン(商品名:サンフェノンBG3,太陽化学株式会社製)をそれぞれが2.75mg/mlとなるように配合した。また、(−)−エピガロカテキンガレート(和光純薬工業株式会社製)を同じ2.75mg/mlとなるようにジェルに配合した。 Specifically, extracted catechin and purified catechin (trade name: Sanphenon BG3, manufactured by Taiyo Kagaku Co., Ltd.) are each 2.75 mg / ml for gel (trade name: Tromake, manufactured by Meiji Dairies Co., Ltd.). Blended into Further, (−)-epigallocatechin gallate (manufactured by Wako Pure Chemical Industries, Ltd.) was blended in the gel so as to have the same 2.75 mg / ml.
被験菌として、代表的口腔常在レンサ球菌、歯周病原菌、Candida、StaphylococcusおよびEscherichiaなどの表1に記載する計25菌株を用いた。 A total of 25 strains described in Table 1 such as representative oral resident streptococci, periodontal pathogens, Candida, Staphylococcus and Escherichia were used as test bacteria.
抗菌作用の測定は、カップ法による寒天拡散法を改良して行った。
具体的には、まず10ml BHI寒天またはGAM寒天(1.5%)で平板培地を作成し、その上に200μl供試菌液/15ml BHI寒天またはGAM寒天(1%,55℃)を重層した。この上に滅菌金属ダボを6〜7ヶ所に静置し、培地硬化後、金属ダボを除去した。こうして出来た穴にそれぞれのジェル200μlを添加して、冷蔵庫に1時間保存した。なお、嫌気培養菌の場合には嫌気培養装置のエントランスボックスに30分間保存した。さらにこの培地を37℃で24時間、好気または嫌気培養を行い、発育後の阻止帯域の直径を測定した。
得られた結果について図1に示す。
The antibacterial action was measured by improving the agar diffusion method using the cup method.
Specifically, first, a plate medium was prepared with 10 ml of BHI agar or GAM agar (1.5%), and 200 μl of the test solution / 15 ml of BHI agar or GAM agar (1%, 55 ° C.) was layered thereon. . On this, a sterilized metal dowel was allowed to stand at 6 to 7 places, and after the medium was cured, the metal dowel was removed. 200 μl of each gel was added to the holes thus prepared and stored in the refrigerator for 1 hour. In the case of an anaerobic culture, it was stored for 30 minutes in the entrance box of the anaerobic culture apparatus. Further, this medium was subjected to aerobic or anaerobic culture at 37 ° C. for 24 hours, and the diameter of the inhibition zone after growth was measured.
The obtained results are shown in FIG.
図1のグラフから判るように、本発明の口腔常在菌叢調整ジェルはすべての病原性を有する菌に対して優れた発育阻止作用、すなわち抗菌効果を示した。また、多くの口腔細菌と共凝集能が高く、歯垢蓄積に重要なActinomycesおよびFusobacteriumに対して顕著な発育阻止作用が認められた。また、う蝕原因菌のStreptococcus mutans、歯周病原菌、CandidaおよびStaphylococcus、MRSAにおいても明確な発育阻止活性が見られた。さらに、本発明の口腔常在菌叢調整ジェルは、正常な口腔環境維持に極めて重要なS. sanguinis、S. oralis、S. gordoniiおよびS. mitisに対しては発育阻止活性は認められなかった。
従って、本発明の口腔常在菌叢調整ジェルは優れた抗菌効果を示す一方、正常常在菌叢には影響を与えないことが判った。即ち、う蝕、歯周病およびCandida症などの原因菌に対してのみ抗菌効果が認められ、優れた口腔常在菌叢調整能を示した。
As can be seen from the graph of FIG. 1, the oral resident flora-adjusting gel of the present invention exhibited an excellent growth inhibitory action, ie, an antibacterial effect, against all pathogenic bacteria. Moreover, a remarkable growth inhibitory action was observed against Actinomyces and Fusobacterium, which have high coaggregation ability with many oral bacteria and are important for plaque accumulation. In addition, a clear growth inhibitory activity was also observed in the caries-causing bacteria Streptococcus mutans, periodontal pathogens, Candida and Staphylococcus, MRSA. Furthermore, the oral resident flora-adjusting gel of the present invention is extremely important for maintaining normal oral environment. sanguinis, S .; oralis, S.M. Gordoni and S. No growth inhibitory activity was observed against mitis.
Therefore, it was found that the oral resident flora adjusting gel of the present invention has an excellent antibacterial effect, but does not affect the normal resident flora. That is, an antibacterial effect was observed only against causative bacteria such as caries, periodontal disease, and Candida disease, and excellent oral resident flora adjusting ability was shown.
[実施例2]口腔微生物に対するカテキンジェルの経時的な抗菌活性
本発明による口腔常在菌叢調整ジェルが、口腔内に残った場合、その抗菌活性は持続しているか否かを検討するため、経時的な抗菌活性について試験を行った。口腔内に本発明の口腔常在菌叢調整ジェルが残存しても、そのままでは残存せずに唾液にカテキンが放出されることが想定される。そこで、カテキンが唾液へ放出されるモデルとして、PBSをジェルの上に添加し、これを試験試料とした。尚、陰性対照にはカテキンを含まないジェルを用いた。
[Example 2] Antibacterial activity of catechin gel over time against oral microorganisms When the oral microbial flora adjusting gel according to the present invention remains in the oral cavity, in order to examine whether or not its antibacterial activity is sustained, The antibacterial activity over time was tested. Even if the oral microbial flora adjusting gel of the present invention remains in the oral cavity, it is assumed that catechin is released into saliva without remaining as it is. Therefore, as a model in which catechin is released into saliva, PBS was added onto the gel, and this was used as a test sample. As a negative control, a gel containing no catechin was used.
具体的には、ジェル(商品名:トロメイク、明治乳業株式会社製)に対して抽出カテキン及び精製カテキン(商品名:サンフェノンBG3,太陽化学株式会社製)を、それぞれが2.75mg/mlとなるように配合した。また、(−)−エピガロカテキンガレート(和光純薬工業株式会社製)を同じ2.75mg/mlとなるようにジェルに配合した。 Specifically, extracted catechin and purified catechin (trade name: Sanphenon BG3, manufactured by Taiyo Kagaku Co., Ltd.) are each 2.75 mg / ml for gel (trade name: Tromake, manufactured by Meiji Dairies Co., Ltd.). It was blended as follows. Further, (−)-epigallocatechin gallate (manufactured by Wako Pure Chemical Industries, Ltd.) was blended in the gel so as to have the same 2.75 mg / ml.
得られたジェル3mlを12穴のマクロタイタープレートのウェル(直径23mm)に入れ、さらに3mlのPBSを重層した。本発明の口腔常在菌叢調整ジェルについては、30、60、180及び360分後の上清(PBS層)を取り除いた残存ジェルのそれぞれを採取し試験に用いた。 3 ml of the obtained gel was placed in a well (diameter: 23 mm) of a 12-well macrotiter plate, and 3 ml of PBS was layered thereon. For the oral resident flora-adjusting gel of the present invention, each of the remaining gels after removing the supernatant (PBS layer) after 30, 60, 180, and 360 minutes was collected and used in the test.
被験菌として、代表的口腔常在レンサ球菌、歯周病原菌、Candida、StaphylococcusおよびEscherichiaなど、前述の表1に記載する計25菌株を用いた。 A total of 25 strains described in Table 1 above, such as representative oral resident streptococci, periodontal pathogens, Candida, Staphylococcus and Escherichia, were used as test bacteria.
抗菌作用の測定は、実施例1と同様にカップ法による改良寒天拡散法により行った。 The antibacterial action was measured by the modified agar diffusion method using the cup method in the same manner as in Example 1.
口腔微生物に対するカテキンジェルの抗菌効果は、いずれの時間においても実施例1と同様の発育阻止作用が見られた。また、口腔内にジェルが残り、唾液等でカテキンが放出されるのを模したPBS上清においては、360分間処理において抗菌効果が認められた。 As for the antibacterial effect of catechin gel against oral microorganisms, the same growth inhibitory action as in Example 1 was observed at any time. In addition, an antibacterial effect was observed in a 360-minute treatment in a PBS supernatant that mimicked that gel remained in the oral cavity and catechin was released with saliva or the like.
[実施例3]市販品との抗菌活性における比較試験
本発明の口腔常在菌叢調整ジェル(カテキン濃度2.75mg/ml)及びカテキンを含有しないジェルのみ、並びに比較として市販品A(主な抗菌成分:ラクトペルオキシダーゼ、グルコースオキシダーゼ、リゾチーム、ラクトフェリン)、市販品B(主な抗菌成分:セチルピリジニウムクロリド)とを用いて、抗菌活性試験を行った。
[Example 3] Comparative test on antibacterial activity with commercially available product Only oral gel categorizing gel (catechin concentration 2.75 mg / ml) and gel containing no catechin of the present invention, and commercially available product A (main) Antibacterial activity tests were performed using antibacterial components: lactoperoxidase, glucose oxidase, lysozyme, lactoferrin) and commercial product B (main antibacterial components: cetylpyridinium chloride).
被験菌として、代表的口腔常在レンサ球菌、放線菌、歯周病原菌、Candida、及びStaphylococcusなどの表2に記載する計10菌株を用いた。 A total of 10 strains described in Table 2 such as representative oral resident streptococci, actinomycetes, periodontal pathogens, Candida, and Staphylococcus were used as test bacteria.
抗菌作用の測定は、実施例1と同様のカップ法による改良寒天拡散法を用いて行った。
得られた結果を図2及び図3に示す。
The antibacterial action was measured using a modified agar diffusion method using the same cup method as in Example 1.
The obtained results are shown in FIGS.
病原性を有する被験菌に対し、本発明の口腔常在菌叢調整ジェルは比較の市販品より強い発育阻止作用を示した。特に市販品AのC. albicans対する作用はまったく認められなかった。また、正常常在菌叢においては、本発明の口腔常在菌叢調整ジェルによる発育阻止作用は認められなかったが、比較の市販品では発育阻止作用が認められた。従って、本発明の口腔常在菌叢調整ジェルは、市販品と比較して、う蝕、歯周病およびCandida症などの原因菌に対する抗菌作用が強く認められる一方、正常常在菌叢には抗菌活性を認めなかったことから、市販品よりも優れた口腔常在菌叢調整能を有することが判った。 For test bacteria having pathogenicity, the oral resident flora-adjusting gel of the present invention showed a stronger growth inhibitory action than the comparative commercial product. In particular, the commercial product A.C. No effect on albicans was observed. Further, in the normal resident flora, the growth inhibitory action by the oral resident flora-adjusting gel of the present invention was not observed, but the growth inhibitory action was observed in the comparative commercial product. Therefore, the oral resident flora-adjusting gel of the present invention has a strong antibacterial action against causative bacteria such as caries, periodontal disease and Candida disease, compared to commercially available products, while normal resident flora has Since the antibacterial activity was not recognized, it was found that it has an ability to adjust oral resident flora superior to that of a commercially available product.
[実施例4]剤型の違いによる口腔内残留試験
口腔内における本発明の口腔常在菌叢調整ジェルの挙動を解析するためにジェル投与後の挙動(唾液による希釈、飲み込み、消失)を想定したモデル系残留試験を実施した。
[Example 4] Residual test in the oral cavity depending on the dosage form In order to analyze the behavior of the oral microbiota-adjusting gel of the present invention in the oral cavity, behavior after gel administration (dilution with saliva, swallowing, disappearance) is assumed. Model system residual test was conducted.
試料としては、本発明の口腔常在菌叢調整ジェル(カテキン含量2.75mg/ml)と、比較のカテキン水溶液(カテキン含量2.75mg/ml)を用いた。 As samples, the oral resident flora adjusting gel of the present invention (catechin content 2.75 mg / ml) and a comparative catechin aqueous solution (catechin content 2.75 mg / ml) were used.
24穴ウェルに本発明の口腔常在菌叢調整ジェルまたはカテキン溶液を充填(3.4ml/ウェル)した。この24穴ウェルプレートをプラスチックコンテナー内に静置し、周囲から人工唾液をプレート上面の1cm上まで注入(340ml)し、1分間静置後、プラスチックコンテナーの下部より人工唾液を排出し、排出液を回収した。この人工唾液の注入と排出を5回繰り返した後、このサンプルを希釈して、OD310nm値を測定(U−1100、日立)した。実験前の溶液およびジェルのカテキン濃度を100%とし、残留率を算出した。得られた結果を図4に示す。 A 24-well well was filled with the oral resident flora-adjusting gel or catechin solution of the present invention (3.4 ml / well). Place the 24-well plate in a plastic container, inject artificial saliva from the surrounding area up to 1 cm above the top of the plate (340 ml), leave it for 1 minute, and then discharge the artificial saliva from the bottom of the plastic container. Was recovered. After the artificial saliva was injected and discharged five times, this sample was diluted and the OD 310 nm value was measured (U-1100, Hitachi). The residual ratio was calculated by setting the catechin concentration of the solution and gel before the experiment to 100%. The obtained results are shown in FIG.
排出1回目において既に残存カテキン量に大幅な違いが認められた。5回の排出が終了した時点で、本発明の口腔常在菌叢調整ジェルでは約90%のカテキンが残留していたが、比較のカテキン溶液ではほとんどカテキンの残留は認められなかった。したがって、本発明の口腔常在菌叢調整ジェルを用いることで、有効成分が長期に渡り残留することが明らかとなった。 A significant difference in the amount of residual catechin was already observed in the first discharge. At the time when the discharge was completed five times, about 90% of the catechin remained in the oral resident flora-adjusting gel of the present invention, but almost no catechin remained in the comparative catechin solution. Therefore, it became clear that an active ingredient remains over a long period of time by using the oral cavity normal flora adjustment gel of this invention.
[実施例5]剤型の違いによる抗菌活性の比較試験
本発明の口腔常在菌叢調整ジェル(カテキン含量2.75mg/ml)と、カテキン水溶液を摂取した場合を模した比較試験を実施した。比較のためのカテキン水溶液は、当該ジェルの4倍濃度(カテキン含量11mg/ml)の試料を用いて、実施例1と同様の試験を行い、それぞれの抗菌活性について測定を行った。カテキン水溶液の場合は、飲み込みを考慮して1分間の処理を行った。なお、被験菌として、代表的口腔常在レンサ球菌、歯周病原菌、Candida、StaphylococcusおよびEscherichiaなどの表3に示す計6菌株を用いた。得られた結果を図5に示す。
[Example 5] Comparative test of antibacterial activity by difference in dosage form A comparative test simulating the case of ingesting the oral resident bacterial flora adjusting gel of the present invention (catechin content 2.75 mg / ml) and a catechin aqueous solution was conducted. . The catechin aqueous solution for comparison was subjected to the same test as in Example 1 using a sample having a 4-fold concentration of the gel (catechin content: 11 mg / ml), and each antibacterial activity was measured. In the case of a catechin aqueous solution, treatment for 1 minute was performed in consideration of swallowing. A total of 6 strains shown in Table 3 such as representative oral resident streptococci, periodontal pathogens, Candida, Staphylococcus and Escherichia were used as test bacteria. The obtained results are shown in FIG.
本発明の口腔常在菌叢調整ジェルを用いた場合、全ての被験菌株において発育阻止作用が認められた。特に比較であるカテキン4倍濃度溶液の1分間処理に対して、本発明の口腔常在菌叢調整ジェルでは非常に顕著な発育阻止作用がすべての被験菌に認められた。 When the oral resident flora-adjusting gel of the present invention was used, the growth inhibitory action was observed in all the test strains. In particular, compared to the 1-minute treatment of the catechin quadruple concentration solution as a comparison, the oral resident flora-adjusting gel of the present invention showed a very remarkable growth inhibitory action in all the test bacteria.
[実施例6]カテキンジェルのヒトにおける有用性の検討
要介護高齢者32名の口腔内Candida量を調べ、Candidaが検出された8名と検出されなかった4名の計12名(男性1名、女性11名、平均年齢87.6±8.8歳)を対象者とした。
[Example 6] Examination of the usefulness of catechin gel in humans The amount of Candida in the oral cavity of 32 elderly people requiring care was examined. A total of 12 persons (8 males in whom Candida was detected and 4 persons in whom Candida was not detected (1 male) 11 women, average age 87.6 ± 8.8 years).
被験者は、夕食後の日常の口腔ケア後、20mlの本発明の口腔常在菌叢調整ジェル(カテキン濃度2.75mg/ml)の一部をスポンジブラシに取り、口腔内全体にまんべんなく塗り、残ったジェルは飲み込んでもらった。これを2ヶ月間行った。唾液サンプルについては、被験者1人あたり、唾液をシードスワブ1号(栄研化学)の2本にしみ込ませた。合計6回のサンプル採取を行った。また、試験2週間後に被験者の口腔状態について専門家(歯科衛生士)によるアンケートを実施した。アンケート内容は図10に示す。
After daily oral care after dinner, the subject took a portion of 20 ml of the oral microbial flora adjusting gel of the present invention (catechin concentration 2.75 mg / ml) on a sponge brush, and evenly applied to the entire oral cavity. The gel was swallowed. This was done for 2 months. About the saliva sample, per subject, the saliva was soaked into two seed swabs No. 1 (Eiken Chemical). A total of 6 samples were collected. Moreover, the questionnaire by the expert (dental hygienist) was implemented about the oral condition of the
採取したサンプルの測定は、シードスワブのサンプルのしみ込んだ先端の綿部分を切り、滅菌PBS(リン酸緩衝液)2mlの入ったチューブに投入した。10秒間超音波処理後、滅菌PBSにて希釈された溶液50μlを、Brain Heart Infusion(BHI)培地、Mitis−Salivarius(MS)培地、0.5Mバシトラシンを含んだMitis−Salivarius(MSB)培地およびCHROM寒天培地にスパイラル装置を用いて接種した。MSおよびMSBは、5%CO2含有好気条件下にて、CHROM寒天培地は好気条件下で37℃、48時間培養後、コロニー数を計算した。BHIは総菌数、MSは総レンサ球菌数、MSBはMutansレンサ球菌数、CHROM寒天培地はCandida数の算定に用いた。
得られた結果を図6から図9に示す。
For the measurement of the collected sample, the cotton part at the tip of the seed swab sample soaked was cut and placed in a tube containing 2 ml of sterile PBS (phosphate buffer solution). After sonication for 10 seconds, 50 μl of a solution diluted with sterile PBS was added to Brain Heart Infusion (BHI) medium, Mitis-Salivarius (MS) medium, Mitis-Salivarius (MSB) medium containing 0.5 M bacitracin and CHROM. The agar medium was inoculated using a spiral device. The number of colonies was calculated after culturing MS and MSB under aerobic conditions containing 5% CO 2 and CHROM agar medium under aerobic conditions at 37 ° C. for 48 hours. BHI was used for calculating the total number of bacteria, MS was used for calculating the total number of streptococci, MSB was used for calculating the number of Mutans streptococci, and the CHROM agar medium was used for calculating the number of Candida.
The obtained results are shown in FIGS.
アンケート調査は、各調査項目で最も良好なもののスコアを1点として、順次悪くなるに従ってスコアが1点づつ増えたものの平均値と標準偏差とを示した。アンケート結果を図11に示す。 The questionnaire survey showed the average value and standard deviation of scores that increased by one point as the score worsened, with the score of the best survey item as 1 point. The questionnaire results are shown in FIG.
本発明の口腔常在菌叢調整ジェル使用後、早期にCandida数の急激な平均値の減少が認められた(12月26日、グラフ中「12/26」と表記する)。しかし、短時間で(1/9)回復するものの、初期値より減少傾向が維持された。減少傾向は維持される(2/5まで)が、本発明のジェルの使用停止後(3/4)、菌数は速やかに回復、そのレベルが4/1まで続いた。S. mutans数もCandida数と同様に、本発明の口腔常在菌叢調整ジェル使用後、短時間で(12/26)減少が認められたが、1/9には回復し、その後初期値に近づいた。総菌数および総レンサ球菌数において本発明の口腔常在菌叢調整ジェルによる影響は特に認められなかった。 After the use of the oral resident flora adjusting gel of the present invention, a rapid decrease in the average value of the Candida number was observed early (denoted as “12/26” in the graph on December 26). However, although it recovered in a short time (1/9), the decreasing tendency was maintained from the initial value. The decreasing trend was maintained (up to 2/5), but after the use of the gel of the present invention was stopped (3/4), the number of bacteria recovered rapidly and the level continued to 4/1. S. As with the Candida number, the mutans number decreased in a short time (12/26) after using the oral microbial flora adjusting gel of the present invention, but recovered to 1/9 and then approached the initial value. It was. The total bacterial count and the total streptococcal count were not particularly affected by the oral bacterial flora adjusting gel of the present invention.
試験2週間後に実施したアンケート結果から、本発明の口腔常在菌叢調整ジェルは口腔内の常在菌の調整のみならず、本発明の口腔常在菌叢調整剤の保湿効果により、口腔内環境も改善していることが判明した。
これらのことから、本発明の口腔常在菌叢調整剤は高齢者の口腔ケアおよびQOLの向上に役立つことが示唆された。
From the results of a questionnaire conducted two weeks after the test, the oral microbial flora-adjusting gel of the present invention is not only adjusted for the normal bacterium in the oral cavity, but also by the moisturizing effect of the oral resident flora-adjusting agent of the present invention. The environment was also improved.
From these, it was suggested that the oral resident flora regulator of the present invention is useful for oral care and QOL improvement of the elderly.
本発明による口腔常在菌叢調整剤は、所定の粘性を有し、歯周病菌、う蝕原因菌、日和見感染症原因菌の少なくとも一種に対しては抗菌活性を示すが、口腔内常在菌には抗菌活性を示さず、かつ高い保湿作用を有するものである。したがって、本発明による口腔常在菌叢調整剤を塗布、歯磨き、経口摂取、喫食などの簡便な手法により適用するのみで、本発明の優れた口腔常在菌叢調整能を利用することができる。これを用いることで、特に介護を必要とするような高齢者の口腔清浄を補助するための短時間で効率のよい口腔ケア用ジェル及び口腔ケア法を提供することができ、さらに保湿効果も付与することができる。 The oral resident flora adjusting agent according to the present invention has a predetermined viscosity and exhibits antibacterial activity against at least one of periodontal disease bacteria, caries-causing bacteria, and opportunistic infection-causing bacteria. Bacteria do not exhibit antibacterial activity and have a high moisturizing action. Therefore, it is possible to utilize the excellent ability to adjust the normal microbial flora of the present invention only by applying the oral microbial flora adjusting agent according to the present invention by a simple method such as application, brushing, oral intake, and eating. . By using this, it is possible to provide an effective oral care gel and oral care method in a short time for assisting oral cleansing of elderly people who particularly require nursing care, and also provides a moisturizing effect. can do.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008230499A JP2010064961A (en) | 2008-09-09 | 2008-09-09 | Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008230499A JP2010064961A (en) | 2008-09-09 | 2008-09-09 | Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010064961A true JP2010064961A (en) | 2010-03-25 |
Family
ID=42190866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008230499A Pending JP2010064961A (en) | 2008-09-09 | 2008-09-09 | Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2010064961A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012211125A (en) * | 2011-03-18 | 2012-11-01 | Lion Corp | Intraoral formulation in container |
JPWO2013100089A1 (en) * | 2011-12-28 | 2015-05-11 | 株式会社明治 | Antibacterial agent for oral cavity and composition for oral care excellent in storage stability |
JP2015157768A (en) * | 2014-02-21 | 2015-09-03 | 学校法人大阪歯科大学 | Oral composition, periodontal disease risk prediction device, and animal periodontal disease treatment method |
JP2015189708A (en) * | 2014-03-28 | 2015-11-02 | サンスター株式会社 | Oral care composition |
JP2016113460A (en) * | 2014-12-15 | 2016-06-23 | ライオン株式会社 | Oral antimicrobial agent and oral composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05944A (en) * | 1991-06-21 | 1993-01-08 | Taiyo Kagaku Co Ltd | Composition for inhibiting adhesion of periodontosis causative microorganism |
JPH09110687A (en) * | 1996-07-23 | 1997-04-28 | Taiyo Kagaku Co Ltd | Cariostatic and anti-periodontitis composition |
JP2007016021A (en) * | 2005-06-06 | 2007-01-25 | Meiji Milk Prod Co Ltd | Oral care composition |
-
2008
- 2008-09-09 JP JP2008230499A patent/JP2010064961A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05944A (en) * | 1991-06-21 | 1993-01-08 | Taiyo Kagaku Co Ltd | Composition for inhibiting adhesion of periodontosis causative microorganism |
JPH09110687A (en) * | 1996-07-23 | 1997-04-28 | Taiyo Kagaku Co Ltd | Cariostatic and anti-periodontitis composition |
JP2007016021A (en) * | 2005-06-06 | 2007-01-25 | Meiji Milk Prod Co Ltd | Oral care composition |
Non-Patent Citations (1)
Title |
---|
JPN6013026448; 田村宗明, 落合邦康: '口腔常在細菌叢に対するカテキン含有ジェル' 口腔衛生学会雑誌 Vol.58, 20080830, p.313 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012211125A (en) * | 2011-03-18 | 2012-11-01 | Lion Corp | Intraoral formulation in container |
JPWO2013100089A1 (en) * | 2011-12-28 | 2015-05-11 | 株式会社明治 | Antibacterial agent for oral cavity and composition for oral care excellent in storage stability |
JP2015157768A (en) * | 2014-02-21 | 2015-09-03 | 学校法人大阪歯科大学 | Oral composition, periodontal disease risk prediction device, and animal periodontal disease treatment method |
JP2015189708A (en) * | 2014-03-28 | 2015-11-02 | サンスター株式会社 | Oral care composition |
JP2016113460A (en) * | 2014-12-15 | 2016-06-23 | ライオン株式会社 | Oral antimicrobial agent and oral composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12226519B2 (en) | Oral compositions | |
CN104010653B (en) | For preventing and treating the composition and method of mouth disease | |
US10850135B2 (en) | Antiseptic-tolerant lactic acid bacteria | |
JP5566007B2 (en) | Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries | |
JP5906011B2 (en) | Oral composition | |
JP2016513631A (en) | Lactobacillus plantarum NCC2936 preparation and oral health | |
JP4440095B2 (en) | Anti-periodontal disease bacteria composition | |
JP6420951B2 (en) | Antibacterial agent for oral cavity and composition for oral care excellent in storage stability | |
JP2010064961A (en) | Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same | |
CN115803005A (en) | Prebiotic and probiotic treatment to alleviate oral dysbiosis and promote ecological balance | |
WO2012001347A1 (en) | Products with oral health benefits | |
JP5544234B2 (en) | Composition for inhibiting periodontal disease growth | |
JP7445910B2 (en) | Oral compositions, oral care products, and foods containing oral resident bacteria regulators | |
JP7423925B2 (en) | Growth promoter of oral bacteria and composition for oral cavity | |
CN109700751A (en) | A kind of antibacterial toothpaste and preparation method thereof | |
KR102438800B1 (en) | Composition for prevention or treatment of oral diseases comprising lactic acid bacteria fermented noni extract as an active ingredient | |
KR20030031490A (en) | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases | |
JP7308561B2 (en) | Oral composition for animals | |
George et al. | Effectiveness of propolis, probiotics and chlorhexidine on streptococcus mutans and candida albicans: An in-vitro study | |
KR101295242B1 (en) | Antibacterial Composition for Inhibiting Oral Bacteria comprising extract of Dianthus superbus | |
El-Shafy et al. | Evaluation of the antimicrobial effect of olive oil extract on Oral microflora | |
JP6918529B2 (en) | Oral composition | |
JP2009274957A (en) | Bactericidal agent against pathogenic bacterium of periodontal disease comprising red longhorn frass as active ingredient | |
WO2024204676A1 (en) | Skin quality improver, allergy inhibitor, and periodontal disease inhibitor | |
EA042202B1 (en) | ANTISEPTIC-RESISTANT LACTIC BACTERIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Effective date: 20110803 Free format text: JAPANESE INTERMEDIATE CODE: A621 |
|
A131 | Notification of reasons for refusal |
Effective date: 20130605 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130717 |
|
A02 | Decision of refusal |
Effective date: 20130807 Free format text: JAPANESE INTERMEDIATE CODE: A02 |